共同研究

(食品医薬品安全評価分析センター)

 

 

元東京大学大学院薬学系研究科 関水和久先生との共同研

Nature Chemical Biology 11,127-133 (2015) doi:10.1038/nchembio.1710

Artucle Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane

Abstract To obtain therapeutically effective new antibiotics, we first searched for bacterial culture supernatants with antimicrobial activity in vitro and then performed a secondary screening using the silkworm infection model. Through further purification of the in vivo activity, we obtained a compound with a previously uncharacterized structure and named it 'lysocin E'. Lysocin E interacted with menaquinone in the bacterial membrane to achieve its potent bactericidal activity, a mode of action distinct from that of any other known antibiotic, indicating that lysocin E comprises a new class of antibiotic. This is to our knowledge the first report of a direct interaction between a small chemical compound and menaquinone that leads to bacterial killing. Furthermore, lysocin E decreased the mortality of infected mice. To our knowledge, lysocin E is the first compound identified and purified by quantitative measurement of therapeutic effects in an invertebrate infection model that exhibits robust in vivoeffects in mammals.

 


 

秋田大学医学部附属病院 薬剤部 三浦昌朋教授との共同研究

Oncotarget, 2018, Vol. 9, (No. 38), pp: 25277-25284 Review Clinical implications of pharmacokinetics of sunitinib malate and N-desethylsunitinibplasmaconcentrationsfor treatment outcome inmetastatic renal cell carcinoma patients.

Abstract:In this study, we examined the association between the pharmacokinetics (PK)level of sunitinib malate (SU) and its metabolite N-desethyl-sunitinib (DSU) in terms of adverse events (AEs) and clinical outcomes in patients with metastatic renal cell carcinoma (mRCC). The PK of sunitinib (SU and DSU) was examined in 26 patients (20 men and 6 women) with mRCC. The associations between SU/DSU C0 and AE occurrence, best response rate, time to treatment failure, progression-free survival (PFS), and overall survival (OS) were investigated. Occurrence of grade 1 or higher hand-foot syndrome and thrombocytopenia (p = 0.002 and 0.024, respectively) was associated with a high concentration before morning intake (C0) level of SU. Low C0 levels of DSU were significantly associated with drug discontinuation due to disease progression (p = 0.035). Patients with DSU C0 level higher than 15.0 ng/mL showed a tendency toward increased PFS (61 weeks vs 12 weeks, p = 0.004) and OS (36 months vs 8 months, p = 0.040). The C0 level of SU and SU + DSU were not associated with prognosis. The higher level of C0 of SU may predict developing AEs and DSU C0 >15.0 ng/mL may lead to better prognosis of patients treated with sunitinib. PK of sunitinib may be useful for determining adequate dosages and prevention of severe AEs. Further studies are required to establish the utility of the PK of sunitinib in patients with mRCC.


秋田大学医学部附属病院 薬剤部 三浦昌朋教授との共同研究

Drug Metabolism and Pharmacokinetics 31(2016)12-20

Review Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods.

Abstract:Analytical methods using high performance liquid chromatography coupled to ultraviolet detection (HPLCeUV) or liquid chromatographyetandem mass spectrometry (LCeMS/MS) have been reported for the quantification of oral tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib in biological fluids. An LCeMS/MS method can simultaneously assay multiple TKIs and their metabolites with high sensitivity and selectivity for low plasma concentrations less than 1 ng/mL. For quantification of imatinib, nilotinib, and dasatinib, a limit of quantification (LOQ) of less than 10 ng/mL, 10 ng/mL, and 0.1 ng/mL, respectively, in the clinical setting is necessary. Because simpler and more cost-efficient methodology is desired for clinical analysis, plasma concentrations of imatinib and nilotinib (target trough concentrations of 1000 ng/mL and 800 ng/mL, respectively) could be assayed by an HPLCeUV method after comparison with results obtained from the standard LCeMS/MS method. However, in the quantification of dasatinib, the LCeMS/MS method that has high sensitivity and selectivity and is free from interference by endogenous impurities is superior to the HPLCeUV method. Highly precise analytical methods are needed for individualized treatment via dose adjustment of oral anticancer drugs, in particular those with low target plasma concentrations less than 10 ng/mL. Copyright © 2015, The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

 


 

農薬パッケージ検査一覧

OP (食品限定残留農薬検査)

生鮮食品とJGAPに特化した農薬をコストパフォーマンス優先で選択したパッケージです。マシスだけのオリジナルサービス。

EFM (輸出食品残留農薬モニタリング検査)

日本の輸出食品に対して相手国の検疫所が行う残留農薬のモニタリング検査を抜粋してパッケージ化しています。マシスだけのオリジナルサービス。※国限定

IFM&IFM-light (輸入食品残留農薬モニタリング検査)

輸入食品に対して検疫所が行う残留農薬のモニタリング検査と100%同じ項目をパッケージ化しています。マシスだけのオリジナルサービス。

FOODS (生鮮食品毎の残留農薬検査)

国内生鮮食品毎に残留農薬の基準値が設定されています。その設定されている農薬だけを生鮮食品毎にパッケージ化しています。マシスだけのオリジナルサービス。

FPp (残留農薬検査)

コストパフォーマンスが最も高いパッケージです。各種食品に対応しています。(生鮮・健康食品・加工食品)マシスだけのオリジナルサービス。

Coming Soon

Residues of veterinary medicinal products

FPv (残留動物用医薬品検査)

コストパフォーマンスが最も高いパッケージです。各種食品に対応しています(生鮮・健康食品・加工食品)マシスだけのオリジナルサービス。

B (残留農薬検査)

残留農薬の基準値を定量限界に設定したコストパフォーマンスが高いパッケージです。生鮮食品に対応しています。マシスだけのオリジナルサービス。

VD&VD-light (残留動物用医薬品モニタリング検査)

輸入食品に対して検疫所が行う動物医薬品のモニタリング検査と100%同じ項目をパッケージ化しています。マシスオリジナルアービス。

CW&MW (飲料水・ミネラルウォーターの残留農薬検査)

CWは、水質管理目標設定全項目をパッケージ化しています。MWは、ミネラルウォーターの残留農薬基準が設定されている全項目をパッケージ化しています。マシスだけのオリジナルサービス。

PetFood (ペットフードの残留農薬検査他)

愛がん動物飼料の成分規格で定められている全19項目をパッケージ化しています。マシスだけのオリジナルサービス。

Feed (飼料の残留農薬検査)

農林水産省の飼料基準、管理基準で飼料毎に定められている項目を各飼料毎にパッケージ化しています。マシスだけのオリジナルサービス

Soil (土壌の残留農薬検査)

土壌に残留性の高い農薬を選定して、パッケージ化しています。マシスだけのオリジナルサービス。

 

MASIS Top  Sitemap

2021 Copyright MASIS All Right Reserved.